(19)
(11) EP 3 426 676 A1

(12)

(43) Date of publication:
16.01.2019 Bulletin 2019/03

(21) Application number: 17713783.3

(22) Date of filing: 09.03.2017
(51) International Patent Classification (IPC): 
C07K 14/005(2006.01)
(86) International application number:
PCT/IB2017/051401
(87) International publication number:
WO 2017/153954 (14.09.2017 Gazette 2017/37)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: 11.03.2016 US 201662307423 P

(71) Applicant: Pfizer Inc.
New York, NY 10017 (US)

(72) Inventors:
  • CHI, Xiaoyuan Sherry
    Tenafly, New Jersey 07670 (US)
  • YANG, Xinzhen
    Woodcliff Lake, New Jersey 07677 (US)

(74) Representative: Pfizer 
European Patent Department 23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14
75668 Paris Cedex 14 (FR)

   


(54) HUMAN CYTOMEGALOVIRUS GB POLYPEPTIDE